Skip to main content
Registration Centre of Human Clinical Trials

DEPARTMENT OF INTERNAL MEDICINE 1

  

INTRODUCTION

 

The Department of Internal Medicine 1 is the largest clinical section of the University of Pécs. The 
department also has the largest number of beds and staff. Educational and research institutes belong to the 
department which operates on two sites. Several new disciplines are represented at the department besides the 
general, integrative internal medicine.
The entire inpatient care provision has been restructured (TIOP2 Project) at the department recently. This 
reorganisation has created new units (angiology, geriatrics, intensive therapy, translational medicine). The 
reorganisation substantially reduced the number of beds to 272. At each site of the department we have 
created modern units which provide one-day care. As part of this process, we have created 11 
non-independent units.

 

Management of Department

 

Director: Prof. Dr. Kálmán Tóth, University Professor
General Deputy Director: Prof. Dr. Róbert Halmosi, University Professor
Head of the Janus Pannonius Klinikai Tömb site: Prof. Dr. Emese Mezősi, University Professor
Head of the Rákóczi út site, Deputy Director of Quality Management: Prof. Dr. László Bajnok, University Professor
Scientific Deputy Director: Prof. Dr. Gábor Késmárky, University Professor
Deputy Director of Education: Dr. Imre Szabó, Associate Professor 
Head of Outpatient Care: Prof. Dr. Áron Vincze, University Professor
Deputy Director of Nursing: Erika Bihari
Business Consultant: Ágnes Ripli
Human Resources Administrator: István Dencs
Head of Secretariat: Erika Cserhalmi Soványné
Education and Scientific Secretary: Marianna Pesti

 

Management of Units

 

Unit of Angiology, Head: Prof. Dr. Gábor Késmárky, University Professor
Unit of Internal Medicine Intensive Care, Head: Dr. Zsolt Márton, Associate Professor
Unit of Endocrinology and Metabolism, Head: Prof. Dr. Emese Mezősi, University Professor
Unit of Metabolism, Head: Prof. Dr. László Bajnok, University Professor
Unit of Gastroenterology, Head: Prof. Dr. Béla Hunyady, University Professor
Unit of Department of Interventional Gastroenterology, Head: Prof. Dr. Áron Vincze, University Professor 
Unit of Translational Medicine, Head: Dr. Patrícia Sarlós, Associate Professor
Unit of Geriatrics, Head: Dr. Judit Huszár, Chief Clinical Physician
Unit of Hematology, Head: Dr. Alizadeh Hussain, Associate Professor
Unit of Infectious Diseases, Head: Dr. Zoltán Péterfi, Associate Professor
Unit of Cardiology, Head: Prof. Dr. Róbert Halmosi, University Professor
Educational Unit of Cardiology, Head: Prof. Dr. Kálmán Tóth, University Professor
Unit of Cardiology Prevention and Rehabilitation, Head: Dr. Eszter Szabados, Associate Professor
Unit of Clinical Pharmacology, Head: Dr. Tamás Habon, Associate Professor
Unit of Pulmonology, Head: Dr. István Ruzsics, Assistant Professor

 

Number of clinical trial investigators with Good Clinical Practice (GCP) certificate : 17 

Number of clinical trial doctors with Good Clinical Practice (GCP) certificate: 40 

Number of specialist doctors with Clinical Pharmacology certificate: 5

 

EQUIPMENT FOR CLINICAL TRIALS

- centrifuge with cooler for processing blood samples 
- calibrated - 20 °C freezer
- calibrated - 70 °C freezer
- calibrated - 96 °C deep freezer
Page 2 (total: 19)
Number of clinical trial investigators with Good Clinical Practice (GCP) certificate : 17 
Number of clinical trial doctors with Good Clinical Practice (GCP) certificate: 40 
Number of specialist doctors with Clinical Pharmacology certificate: 5
I. NO. INTERNAL MEDICINE CLINIC
Published on the University of Pécs website (https://kvkk.pte.hu)
- sterile rooms
- facilities for autologous stem cell transplantation 
- fibroscan
- calibrated min – max thermometers
- a closed, air-conditioned room for refrigerated and room-temperature storage of test preparations, well 
separated from the medication required for daily patient care
- aseptic laminar flow hood suitable for drug preparation
- tested and calibrated basic devices for measuring vital parameters (blood pressure monitors, 
weight measurement devices, EKG devices)
- closed archiving room

 

 

REFERENCE CLINICAL TRIALS

  

 PROTOCOL IDENTIFERCLINICAL TRIAL NAMEPRINCIPAL INVESTIGATOR 
1.20110118FOURIERProf. Dr. Kálmán Tóth  
2.CL3-09490-144EUROPAProf. Dr. Kálmán Tóth  
3.2017625VESALIUSProf. Dr. Kálmán Tóth  
4.112025-002PROMPTProf. Dr. Emese Mezősi  
5. CH-ACM-01CHIASMAProf. Dr. Emese Mezősi  
6. 747-303REGENERATEProf. Dr. Áron Vincze
7. MLN002-C13008GEMINI I-IIProf. Dr. Áron Vincze
8. PRAN-16-52PRANDr. Hussain Alizadeh 
9. DEBIO 1562-201DEBIODr. Hussain Alizadeh 
10. SHP634-101SHIREDr. Tamás Habon  
11. AZP-3601-CLI-001AMOLYTDr. Tamás Habon  
12. KCP-330-009SADALDr. Ágnes Nagy  
13. BAY80-6946_17067CHRONOS-3Dr. Árpád Szomor

 

OUR PUBLICATIONS 

GIUGLIANO, R., PEDERSEN, T., PARK, J., DE FERRARI, G., M., GACIONG, Z., CESKA, R.,TOTH, K. , GOUNIBERTHOLD, I., LOPEZ-MIRANDA, J., SCHIELE, F., MACH, F., OTT, R., KANEVSKY, E., LIRA-PINEDA, A., SOMARATNE, 
R., WASSERMAN, S. ., KEECH, A., SEVER, P., SABATINE, M. Clinical efficacy and safety of achieving very low LDLCLDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the 
FOURIER trial. Lancet, DOI: 10.1016/S0140-6736(17)32290-0, 2017. Impact factor: 53.254 

MURPHY, SA, PEDERSEN, TR, GACIONG, ZA, CESKA, R., EZHOV, MV, CONNOLLY, D., JUKEMA, JW,TOTH, K. , 
TIKKANEN, MJ, IM, K., WIVIOTT, SD, KURTZ, CE, HONARPOUR, N., GIUGLIANO, R.
P., KEECH, AC, SEVER, PS, SABATINE, MS, on behalf of the FOURIER Investigators. Effect of the PCSK9 Inhibitor 
Evolocumab on Total Cardiovascular Events in Patients with Cardiovascular Disease: A Prespecified Analysis from 
the FOURIER Trial. Jama Cardiology, DOI:
10.1001/jamacardio.2019.0886, 4, 613-619, 2019. Impact factor: 12.794

GAL, R., PRAKSCH, D., KENYERES, P., RABAI, M.,TOTH, K. , HALMOSI, R., HABON, T. Hemorheological alterations in patients with heart failure with reduced ejection fraction treated by resveratrol. Cardiovasc Ther., DOI: 
10.1155/2020/7262474, 2020. Impact factor: 3.023

GAL, R., DERES, L., HORVATH, O., EROS, K., SANDOR, B., URBAN, P., SOOS, SZ., MARTON, ZS., SUMEGI, B.,TOTH, K
., HABON, T., HALMOSI, R. Resveratrol improves heart function by moderating inflammatory processes in 
patients with systolic heart failure. Antioxidants, doi: 10.3390/antiox9111108. 2020. Impact factor: 6.312 

GAL, R., DERES, L.,TOTH, K. , HALMOSI, R., HABON, T. The effect of resveratrol on the cardiovascular system From molecular mechanisms to clinical results. Int J Mol Sci, DOI: 10.3390/ijms221810152, 2021. Impact factor: 6.208  

BIRO, K., FEHER, G., VEKASI, J., KENYERES, P.,TOTH, K ., KOLTAI, K. Hemorheological parameters in diabetic 
patients: Role of glucose lowering therapies. Metabolites, 11, 806, DOI: 10.3390/metabo11120806, 2021. Impact 
factor: 5.581

MELMED S, POPOVIC V, BIDLINGMAIER M, MERCADO M, VAN DERLELY AJ, BIERMASZ N, BOLANOWSKI M, 
COCULESCU M, SCHOPOHL J, RACZ K, GLASER B, GOTH M, GREENMAN Y, TRAINER P,MEZOSI E , SHIMON I, 
GIUSTINA A, KORBONITS M, BRONSTEIN MD, KLEINBERG D, TEICHMAN S, GLIKO-KABIR I, MAMLUK R, HAVIV A, 
STRASBURGER C. Safety and efficacy of oraloctreotide in acromegaly: results of a multicenter phase III trial.J. Clin 
Endocrinol Metab. 2015 Apr;100(4):1699-708, 2015. Impact factor: 5.531

FREDRIK H SCHJESVOLD, MELETIOS-ATHANASIOS DIMOPOULOS, FH SCHJESVOLD, MA DIMOPOULOS, S 
DELIMPASI, P ROBAK,HUSSAIN ALIZADEH , ALAIN ZANNETTI ET AL. Melflufen or pomalidomide plus 
dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-tohead, open-label, phase 3 study. The Lancet Hematology 2022; 9(2):e98-e110. 2022. Impact factor: 18.959 (D1) 

VINCZE A. , PEYRIN-BIROULET L, HART A, BOSSUYT P, LONG M, ALLEZ M, JUILLERAT P, ET AL. Etrolizumab as 
induction and maintenance therapy for ulcerative colitis in patients previously treated with tumor necrosis factor 
inhibitors (HICKORY): a phase 3, randomized, controlled trial. Lancet Gastroenterol Hepatol. 2022;7(2):128-40. 
2022. Impact factor: 45.042 

VINCZE A. , ZEUZEM S, FLISIAK R, VIERLING JM, MAZUR W, MAZZELLA G, THONGSAWAT S, ET AL. Randomized 
clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic 
HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015;42(7):829-44. 2015. Impact factor: 
6.320 

MANNSTADT M, CLARKE BL, VOKES T, BRANDI ML, RANGANATH L, FRASER WD, LAKATOS P,CHAMPION L , 
GARCEAU R, MOSEKILDE L, LAGAST H, SHOBACK D, BILEZIKIAN JP. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebocontrolled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013 Dec;1(4):275-83.
2013. Impact factor (2014): 9.185 

STRASBURGER CJ, VANUGA P, PAYER J, PFEIFER M, POPOVIC V,CHAMPION L ,GÓTH M, OLŠOVSKÁ V, 
TREJBALOVÁ L, VADASZ J, FIMA E, KOREN R, AMITZI L, BIDLINGMAIER M, HERSHKOVITZ O, HART G, BILLER BMK. 
MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 
study in growth hormone-deficient adults. Eur J Endocrinol. 2017
Mar;176(3):283-294. 2017. Impact factor: 4.333

PRINCIPAL INVESTIGATORS

 

 

Prof. Dr. Kálmán Tóth

Tóth Kálmán

SCIENTIFIC DEGREE 

Doctor of the Hungarian Academy of Sciences  

POSITION

University Professor

QUALIFICATIONS 

Anaesthesiology – Intensive therapy, Internal medicine, Cardiology  

SCIENTIFIC INTEREST

cardiology (stable coronary artery disease, arrhythmia, heart 
failure, hyperlipidemia, hypertension)

REFERENCE CLINICAL TRIALS 

CL3-09490-144, EUROPA, Phase 3, Effects of perindoprilon mortality/ 
morbidity in patients with stable coronary artery disease without 
clinical heart failure: a double-blind, multicentre, randomized trial, 
Number of patients: 38

 

20110118, FOURIER, Phase 3, A Double-blind, Randomized, Placebocontrolled, Multicentre Study Assessing the Impact of Additional 
LDL-Cholesterol Reduction on Major Cardiovascular Events When 
AMG 145 is Used in Combination With Statin Therapy In Patients 
with Clinically Evident Cardiovascular Disease. 
Number of patients included: 22

 

CV102-023B, SWORD, Phase 3, The effect of oral d-sotalolone 
mortality in patients with artheriosclerotic coronary heart disease 
and left ventricular dysfunction. 
Number of patients : 16

 

AMGEN 20170625, VESALIUS, A double-blind, randomized, placebocontrolled, multi-site study to evaluate the effect of evolocumab on serious 
cardiovascular events in high cardiovascular risk patients without prior 
myocardial infarction and stroke. 
Number of patients: 15 

 
AVAILABLE FOR PERFORMING
CLINICAL TRIALS  

Phase 2-4

 

 

 

 

 

Prof. Dr. Róbert Halmosi

Halmosi Róbert 

SCIENTIFIC DEGREE

Doctor of the Hungarian Academy of Sciences

 

POSITION

Deputy General Director, University Professor

QUALIFICATIONS 

Internal medicine, Cardiology 

SCIENTIFIC INTEREST

Experimental heart failure, 
Prevention of organ damage by heart failure

REFERENCE CLINICAL TRIALS 

DAPA ACT HF-TIMI 68 (D1690C00078) A
multicenter, randomized, double-blind, parallelgroup, placebo-controlled study to evaluate the 
effect of in-hospital dapagliflozin on clinical
outcomes in hospitalized patients with acute 
heart failure stabilized. Phase 3/b. 
Number of patients: 11 

AVAILABLE FOR PERFORMING CLINICAL TRIALS 

Phase 2-4

 

Prof. Dr. Emese Mezősi 

Mezősi Emese

SCIENTIFIC DEGREE

az MTA doktora

POSITION 

University Professor

QUALIFICATIONS

Internal medicine, Endocrinology 

SCIENTIFIC INTEREST 

endocrinology, neuroendocrine tumors, thyroid tumors, pituitary 
adenomas

REFERENCE CLINICAL TRIALS 

CH-ACM-01, Chiasma, Phase 3. 
Number of patients: 5
D-FR-10380-002, A multicenter, open-label, single-arm, two-stage, 
phase II/a study of the pharmacodynamics of repeated subcutaneous 
administration of BIM23B065, its pharmacokinetics, safety and efficacy
for evaluation in patients with acromegaly. 
Number of patients: 2
CORT125134-451,II of the safety and efficacy of CORT125134. phase test 
of the endogenous Cushing's syndrome
in its management.
Number of patients: 2
AVAILABLE FOR PERFORMING 
CLINICAL TRIALS 
Phase 2-4

 

 

 

 

Prof. Dr. Béla Hunyady 

Hunyadi Béla

SCIENTIFIC DEGREE 

Doctor of the Hungarian Academy of Sciences

POSITION 

University Professor, Head of Unit

QUALIFICATIONS 

Internal medicine, Gastroenterology, Clinical
Pharmacology

SCIENTIFIC INTEREST 

 Basic research related to ulcer disease in 
experimental animal models (mucosal defense
mechanisms, experimental investigation of 
secretion inhibitors and antacids)
- Human studies of antiulcer drugs using the 
endoscopic method and 24-hour intragastric 
pH monitoring.
- Investigation of biogenic amines (histamine, 
dopamine), bioactive peptides (gastrin, 
somatostatin) and their receptors (histamine, 
dopamine, somatostatin, muscarinic receptors) 
in the gastrointestinal tract by 
immunohistochemistry and in situ hybridization 
methods in rodents and humans. Investigation 
of the function of mediators and their receptors 
in experimental models.
- The epidemiology and genetic
background of liver diseases,
examination of its pathomechanism and clinical 
characteristics, with particular regard to chronic 
viral hepatitis.
- Principal investigator of more than 10 clinical 
trials (Phase II-IV) in fields of inflammatory bowel
diseases, liver diseases, peptic ulcer disease and 
reflux disease. 

REFERENCE CLINICAL TRIALS

PB016-03-01 Randomized, Double-Blind, 
Multicentre, Phase III Study of the Efficacy, Safety,
and Immunogenicity of PB016 and Entyvio® in the induction and maintenance of 
clinical response and remission in patients 
with moderate to severe active ulcerative 
colitis (UC) (UCESIVE). 

AVAILABLE FOR PERFORMING CLINICAL TRIALS

Phase 1-4

Prof. Dr. Gábor Késmárky 

Késmárky Gábor

SCIENTIFIC DEGREE

Doctor of the Hungarian Academy of Sciences 

 

POSITION 

University Professor, Deputy Director of Science

QUALIFICATIONS

Internal medicine, cardiology, Internal medicine
Angiology

SCIENTIFIC INTEREST 

cardiology, angiology, haemorheology

REFERENCE CLINICAL TRIALS 

Evolution of hemorheological parameters in clinical
patient groups.
Investigation of the effect of compression 
bandages on the arterial circulation of the lower 
limbs in diseases of different etiologies
Non-invasive angiological diagnostics in a patient 
population with an increased risk of peripheral 
coronary artery disease.
Factors influencing the blood and oxygen supply of 
limbs in peripheral coronary artery disease.

COLA 20190218: Phase 2, randomized, placebocontrolled, double-blind, dose-finding study to 
evaluate the efficacy, safety and tolerability of AMG 
133 in overweight or obese adult patients with or 
without Type 2 diabetes.
Number of patients: 3

WHAT EXAMS DOES IT UNDERTAKE 

Phase 2-4

 

Prof. Dr. Áron Vincze 

Vincze Áron

SCIENTIFIC DEGREE 

PhD, Med. habil.

POSITION

University Professor, Head of Unit

QUALIFICATIONS 

Internal medicine, Gastroenterology

SCIENTIFIC INTEREST 

gastroenterology (inflammatory
bowel disease, liver disease) 

REFERENCE CLINICAL TRIALS 

GEMINI I-II and its long-term extension: 
Vedolizumab in Crohn's disease and ulcerative
colitis.
Number of patients: 7 (currently 4 patients
have been receiving the active ingredient for 
more than 5 years in a long-term in extension 
of the study 

AVAILABLE FOR PERFORMING CLINICAL TRIALS 

 

Phase 3-4 

 

Dr. Alizadeh Hussain

 Alizadeh Hussain

SCIENTIFIC DEGREE 

PhD., Med. habil.

POSITION 

University Associate Professor, Head of Unit

QUALIFICATIONS 

Internal medicine, Hematology, Clinical oncology, Clinical pharmacology 

SCIENTIFIC INTEREST 

hematology (myeloproliferative neoplasias) 

REFERENCE CLINICAL 
TRIALS 		PRAN 16-52: A PHASE III, Double-Blind, Placebo-Controlled, Multicenter, 
Randomized Study of Pracinostat in Combination With Azacitidine in 
Patients >- 18 Years with Newly Diagnosed Acute Myeloid Leukemia unfit 
for Standard Induction Chemotherapy.
Number of patients: 6 
DEBIO 1562-201:, A PHASE 2 Study to Evaluate the Efficacy and 
Tolerability of Debio 1562 in Combination with Rituximab in Patients with 
Relapsed and/or Refractory Diffuse Large B-Cell
Lymphoma and Other Forms of Non-Hodgkin's Lymphoma. 
Number of patients: 5 
AVAILABLE FOR
PERFORMING CLINICAL
TRIALS 

Phase 1-3

 

 

 

 

Dr. Tamás Habon

 Habon Tamás

SCIENTIFIC DEGREE 

PhD., Med. habil.

POSITION 

University Associate Professor, Head of Unit 

QUALIFICATIONS

Internal medicine, Cardiology, Clinical Pharmacology

SCIENTIFIC INTEREST

cardiology (heart failure, atrial fibrillation, hyperlipidemia, 
coronary artery disease)
REFERENCE CLINICAL 
TRIALS 

NCT02781844, SHIRE - SHP634-101, Fázis 1, An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once-Daily and Twice-Daily Dose Regimens of recombinant human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects with Hypoparathyroidism, bevont betegek száma: n.a.

 

NCT00262600, RE-LY - 1160.26: Phase 3, Randomized Evaluation of 
Long Term Anticoagulant Therapy (RE-LY) With Dabigatran 
Etexilate.
Number of patients : N/A
NCT01035255, PARADIGM-HF - CLCZ696B2314: Phase 3, The Efficacy 
and Safety of LCZ696 Compared to Enalaprilon Morbidity and 
Mortality of Patients With Chronic Heart Failure.
Number of patients: N/A
AZP-3601-CLI-001: Phase 1, A SINGLE AND MULTIPLE ASCENDING 
DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, 
PHARMACOKINETICS, AND PHARMACODYNAMICS OF AZP-3601, A 
SYNTHETIC PARATHYROID HORMONE ANALOGUE, IN HEALTHY SUBJECTS 
AND IN SUBJECTS WITH HYPOPARATHYROIDISM. 
Number of patients: 6 

REFERENCE CLINICAL TRIALS 

Phase 1-4

 

 

 

Dr. Szabolcs Kosztolányi 

 Kosztolányi Szabolcs

SCIENTIFIC DEGREE 

PhD

POSITION 

Chief Physician

QUALIFICATIONS

Internal medicine, Hematology

SCIENTIFIC INTEREST 

Cytogenetic prognostic factors in hematological malignancies
 

REFERENCIA VIZSGÁLATOK

CPI-0610-04-MANIFEST-2: A Phase 3, Randomized, Doubleblind, Active-Control Study of CPI-0610 and Ruxolitinib vs. 
Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients.
Number of patients: N/A
XPORT-MF-035: A Phase 2, Randomized, Open-label,
Multicenter Study to Evaluate Safety and Efficacy of Single Agent 
Selinexor Versus Treatment of Physicians' Choice in Patients
with Previously Treated Myelofibrosis.
Number of patients: N/A

REFERENCE CLINICAL TRIALS 

Phase 2-4

 

 

 

Dr. Gabriella Pár 

 Pár Gabriella

SCIENTIFIC DEGREE 

PhD., Med. habil.

POSITION 

University Associate Professor

QUALIFICATIONS 

Internal medicine, Gastroenterology

SCIENTIFIC INTEREST 

hepatology, chronic viral hepatitis, non-alcoholic fatty liver, 
cirrhosis, autoimmune liver disease
REFERENCE CLINICAL 
TRIALS		REGENERATE, NASH study active ingredient: obeticholic acid, Phase 3. 
Number of patients: 5 
ESSENTIAL II, HCV study - active substance: alisporovir + PEG 
IFN+RBV, Phase 3. 
Number of patients: 4

WHAT TESTS

Phase 2-4

 

 

 

 

Dr. Zoltán Péterfi

 Péterfi Zoltán

SCIENTIFIC DEGREE 

PhD, Med. habil. 

POSITION 

University Associate Professor, Head of Unit

QUALIFICATIONS 

Infectology, Internal medicine 

SCIENTIFIC INTEREST 

clostridium difficile infectio, CAP

REFERENCE CLINICAL TRIALS 

2819-MA-1002: ParexelExtend, Phase 3-4. 
Number of patients : 2
2819-MA-1004: Spectrum, Phase 4.
Number of patients: 12
CE01-301: Cempra, Phase 3. 
Number of patients: 1
AVAILABLE FOR 
PERFORMING CLINICAL 
TRIALS 

Phase 3-4

 

 

 

 

Dr. Patrícia Sarlós 

 Sarlós Patrícia

SCIENTIFIC DEGREE 

PhD

POSITION 

University Associate Professor

QUALIFICATIONS 

Internal medicine, Gastroenterology, Clinical pharmacology 

SCIENTIFIC INTEREST

inflammatory bowel diseases, endoscopic ultrasound      

REFERENCE CLINICAL 
TRIALS		MLN0002-3026, VARSITY: Phase 3, A Randomized, Double-Blind, 
Double-Dummy, Multicenter, Active-Controlled Study to 
Evaluate the Efficacy and Safety of Vedolizumab IV Compared to 
Adalimumab SC in Subjects With Ulcerative Coliti. 
Number of patients: N/A
GA28950: Phase 3, Double Blind, Placebo-Controlled, Multicenter 
Study of the Efficacy and Safety of Etrolizumab During Induction and 
Maintenance in Patients with Moderate to Severe Active Ulcerative 
Colitis Who Are Refractory to or Intolerant of TNF Inhibitors.
Number of patients: N/A
CNTO1275CRD3002, UNITI 2: Phase 3, Randomized, Doubleblind, 
Placebo-controlled, Parallel-group, Multicenter Study to Evaluate 
the Safety and Efficacy of Ustekinumab Induction Therapy in 
Subjects with Moderately to Severely Active Crohn's Disease.
Number of patients: N/A
AVAILABLE FOR PERFORMING 
CLINICAL TRIALS 

Phase 1-4

 

 

 

 

 

Dr. Árpád Szomor

 Szomor Árpád

SCIENTIFIC DEGREE 

PhD

POST 

Chief Clinical Physician

QUALIFICATIONS

Internal medicine, Hematology

SCIENTIFIC
SUBJECT OF INTEREST		lymphoma (Hodgkin, non-Hodgkin), myeloma, autologous 
transplantation

REFERENCE CLINICAL TRIALS

BAY80-6946/17667: Chronos 3 and Chronos 4, Indolent 
lymphoma, Phase 3. 
Number of patients: 7 and 3
2011-003 Amgen/Onyx (myeloma), Phase 3. 
Number of patients: 6
PX 171-011: Myeloma, Phase 3, 
Number of patients: 6

CLINICAL TRIALS

Phase 3-4

 

 

 

STUDY TEAM 

 

 

Study Coordinators

 

We employ 3 study nurses in clinical trials. In addition to that, 3 central coordinators ("Flying 
Coordinators") help the successful implementation of clinical trials.

 Number of study coordinators with master degree (MSc): 1 Number
of study coordinators with bachelor degree (BSc): 2 Number of study
coordinators with further education degree: 0

In addition, 3 central coordinators ("Flying Coordinators") help the successful conduct of human clinical trials.

Name

Phone

Email

Eva Csavari 

+36 30 583 8743

kovacs.eva67@pte.hu [5]

Gábor Kollár

+36 30 542 4314

kollar.gabor@pte.hu [4]

Györgyi Gregor Kovácsné 

+36 20 577 4898

studycoordinator@pte.hu

Szilvia Levang Kovácsné

+36 20 480 3905

kovacsne.szilvia@pte.hu

Edina G. Schaffer

+36 70 368 7397

studycoordinator@pte.hu [6] 

Csilla Szalontay 

+36 30 211 0326

studycoordinator@pte.hu [6] 

 

 

Study Nurses

 

There are 15 people who work as study nurses at the department. 
Page 17 (total: 19)
Number of study nurses with master degree (MSc): 1 Number of study 
nurses with bachelor degree (BSc): 6
Number of study nurses with further education degree: 7

 

NamePhoneEmail
Brigitta Albert+36 30 447 2335albert.brigitta@pte.hu [8]
Éva Csavari+36 30 583 8743kovacs.eva67@pte.hu [9]
Anna Faluvégi

+36 72 536 000

(32638-as mellék)

faluvegi.anna@pte.hu
Hajnalka Kaproncai kaproncai.hajnalka@pte.hu [11]
Mónika Dárdai Kesztyűsné+36 30 400 6229dardai.monika@pte.hu [12]
Gábor Kollár+36 30 542 4314kollar.gabor@pte.hu [4]
Györgyi Gregor Kovácsné+36 20 577 4898studycoordinator@pte.hu [6]
Szilvia Levang Kovácsné+36 20 480 3905kovacsne.szilvia@pte.hu [7]
Adrienn Litz+ 36 30 831 8892litz.adrienn@pte.hu [13]
Ágnes Molnár+ 36 30 908 0755molnar.agnes@pte.hu [14]
Edina G. Schäffer+36 70 368 7397studycoordinator@pte.hu [6]
Csilla Szalontay+36 30 211 0326studycoordinator@pte.hu [6]
Kornélia Fazekas Tapasztóné+36 30 446 0919fazekas.kornelia@pte.hu [5]
Ildikó Vezmárovics

+36 72 536 000

(32665-ös mellék)

vezmarovics.ildiko@pte.hu [15]

References
[1] file:///C:/Users/tojgaca.pte/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/ZS878FT S/
KVKK%20honlap%20aktualiz%C3%A1l%C3%A1sa_v%C3% A9gleges.docx#_msocom_1 [2] file:///C:/ Users/
tojgaca.pte/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/ZS878FTS/KVKK%20 
website%20aktualiz%C3%A1l%C3 %A1sa.docx#_msocom_1 [3] file:///C:/Users/tojgaca.pte/AppData/Local/
Microsoft/Windows/INetCache/Content.Outlook/ZS878FTS/KVKK%20honlap%20aktualiz%C3%A1l
Page 18 (total: 19)
I. NO. INTERNAL MEDICINE CLINIC
Published on the University of Pécs website (https://kvkk.pte.hu)
%C3%A1sa.docx#_msoanchor_1 [4] mailto: kollar.gabor@pte.hu [5] mailto: ovacs.eva67@pte.hu [6] mailto: 
studycoordinator@pte.hu [7] mailto: kovacsne.szilvia @pte.hu [8] mailto: albert.brigitta@pte.hu [9] mailto: 
kovacs.eva67@pte.hu [10] mailto: faluvegi.anna@pte.hu [11]
mailto: kaproncai.hajnalka@pte.hu [12] mailto: dardai.monika@pte.hu [13] mailto: litz.adrienn@pte.hu [14] mailto: 
molnar.agnes@pte.hu [15] mailto: fazekas.kornelia@pte.hu [16]
mailto: vezmarovics.ildiko@pte.hu

 

 

 

 

 

Létrehozva: 2019.08.01.

Utoljára frissítve: 2019.09.04.